1 Guidance

1 Guidance

1.1 Pixantrone monotherapy is recommended as an option for treating adults with multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma only if:

  • the person has previously been treated with rituximab and

  • the person is receiving third- or fourth-line treatment and

  • the manufacturer provides pixantrone with the discount agreed in the patient access scheme.

1.2 People currently receiving treatment initiated within the NHS with pixantrone monotherapy that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

  • National Institute for Health and Care Excellence (NICE)